{"id":7527,"date":"2026-01-05T21:20:01","date_gmt":"2026-01-06T05:20:01","guid":{"rendered":"http:\/\/54.162.83.219\/?p=7527"},"modified":"2026-01-05T21:20:03","modified_gmt":"2026-01-06T05:20:03","slug":"da-1726-obesity-drug-glp1-alternative","status":"publish","type":"post","link":"https:\/\/guru.today\/?p=7527","title":{"rendered":"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control"},"content":{"rendered":"\n<figure class=\"wp-block-image alignwide size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"526\" src=\"http:\/\/54.162.83.219\/wp-content\/uploads\/DongA-1024x526.png\" alt=\"\" class=\"wp-image-7531\" srcset=\"https:\/\/guru.today\/wp-content\/uploads\/DongA-1024x526.png 1024w, https:\/\/guru.today\/wp-content\/uploads\/DongA-300x154.png 300w, https:\/\/guru.today\/wp-content\/uploads\/DongA-768x395.png 768w, https:\/\/guru.today\/wp-content\/uploads\/DongA-1536x789.png 1536w, https:\/\/guru.today\/wp-content\/uploads\/DongA.png 1900w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">(Photo=Dong-A ST)<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">MetaVia, a U.S.-based clinical-stage biotechnology company affiliated with Dong-A ST, a South Korean pharmaceutical company, has released early clinical data suggesting that the next phase of obesity treatment may extend beyond GLP-1\u2013only drugs that now dominate the U.S. market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In Phase 1b results disclosed this week, the company said its experimental therapy, DA-1726, demonstrated favorable safety and tolerability while producing rapid weight loss alongside improvements in blood glucose and liver-related markers. The findings come as clinicians and drugmakers search for options that address limitations of existing GLP-1 therapies, including dose escalation burdens and limited impact on obesity-related liver disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The eight-week study evaluated a fixed, non-titrated 48 mg dose in adults with obesity, a design that contrasts with the gradual dose escalation required for most current injectable treatments. According to the company, no treatment-related discontinuations were reported, and gastrointestinal adverse events were largely mild to moderate.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DA-1726 is designed to activate both the GLP-1 receptor and the glucagon receptor, mimicking the activity of the hormone oxyntomodulin. The dual mechanism aims to suppress appetite while increasing energy expenditure, an approach researchers believe may lead to greater reductions in visceral fat than GLP-1 drugs alone.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By day 26, participants recorded an average weight loss of 6.1%, with waist circumference reduced by 2.3 inches. By day 54, average weight loss reached 9.1%, and waist circumference declined by 3.9 inches. Fasting blood glucose improved by an average of 12.3 mg\/dL, easing concerns that glucagon activity could destabilize glycemic control.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Liver-related outcomes were among the more notable findings. Measurements using vibration-controlled transient elastography showed liver stiffness declined by 23.7% from baseline over the eight-week period. The technique is recognized by the U.S. Food and Drug Administration as a noninvasive biomarker in the development of treatments for metabolic dysfunction\u2013associated steatohepatitis, or MASH.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hyung Hun Kim, MetaVia\u2019s chief executive, said the data suggest that combining glucagon signaling with GLP-1 activity may enhance reductions in abdominal fat without compromising blood glucose stability. He added that the absence of mandatory dose titration could improve adherence in real-world clinical settings, where discontinuation remains a challenge.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MetaVia plans to expand its clinical program with a 16-week study testing a single-step escalation to 48 mg and a two-step escalation to 64 mg. Results are expected later this year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase 1b trial enrolled adults with obesity defined as a body mass index of 30\u201345 kg\/m\u00b2 in a randomized, double-blind, placebo-controlled design. While the findings remain preliminary, they reflect a broader effort in the U.S. obesity drug landscape to move beyond weight loss alone and address the metabolic complications that often accompany it.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MetaVia, a U.S.-based clinical-stage biotechnology company affiliated with Dong-A ST, a South Korean pharmaceutical company, has released early<\/p>\n","protected":false},"author":7,"featured_media":7531,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[38,32,54],"tags":[],"class_list":["post-7527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-stories","category-everyday-economy","category-top-section"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>New Obesity Drug Targets Liver, Glucose Beyond GLP-1<\/title>\n<meta name=\"description\" content=\"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/guru.today\/?p=7527\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control\" \/>\n<meta property=\"og:description\" content=\"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/guru.today\/?p=7527\" \/>\n<meta property=\"og:site_name\" content=\"GURU TODAY\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T05:20:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T05:20:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/guru.today\/wp-content\/uploads\/DongA-1024x526.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"526\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jin Lee\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jin Lee\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527\"},\"author\":{\"name\":\"Jin Lee\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/person\\\/976030a4a8c104a0b509402bcb2a0631\"},\"headline\":\"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control\",\"datePublished\":\"2026-01-06T05:20:01+00:00\",\"dateModified\":\"2026-01-06T05:20:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527\"},\"wordCount\":448,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/DongA.png\",\"articleSection\":[\"All Stories\",\"Everyday Economy\",\"Top section\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/guru.today\\\/?p=7527#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527\",\"url\":\"https:\\\/\\\/guru.today\\\/?p=7527\",\"name\":\"New Obesity Drug Targets Liver, Glucose Beyond GLP-1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/DongA.png\",\"datePublished\":\"2026-01-06T05:20:01+00:00\",\"dateModified\":\"2026-01-06T05:20:03+00:00\",\"description\":\"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/guru.today\\\/?p=7527\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#primaryimage\",\"url\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/DongA.png\",\"contentUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/DongA.png\",\"width\":1900,\"height\":976},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=7527#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/guru.today\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/guru.today\\\/#website\",\"url\":\"https:\\\/\\\/guru.today\\\/\",\"name\":\"GURU TODAY\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/guru.today\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\",\"name\":\"GURU TODAY\",\"url\":\"https:\\\/\\\/guru.today\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/54.162.83.219\\\/wp-content\\\/uploads\\\/Logo_white-1.png\",\"contentUrl\":\"http:\\\/\\\/54.162.83.219\\\/wp-content\\\/uploads\\\/Logo_white-1.png\",\"width\":1000,\"height\":167,\"caption\":\"GURU TODAY\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/person\\\/976030a4a8c104a0b509402bcb2a0631\",\"name\":\"Jin Lee\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"caption\":\"Jin Lee\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New Obesity Drug Targets Liver, Glucose Beyond GLP-1","description":"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/guru.today\/?p=7527","og_locale":"en_US","og_type":"article","og_title":"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control","og_description":"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.","og_url":"https:\/\/guru.today\/?p=7527","og_site_name":"GURU TODAY","article_published_time":"2026-01-06T05:20:01+00:00","article_modified_time":"2026-01-06T05:20:03+00:00","og_image":[{"width":1024,"height":526,"url":"https:\/\/guru.today\/wp-content\/uploads\/DongA-1024x526.png","type":"image\/png"}],"author":"Jin Lee","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jin Lee","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/guru.today\/?p=7527#article","isPartOf":{"@id":"https:\/\/guru.today\/?p=7527"},"author":{"name":"Jin Lee","@id":"https:\/\/guru.today\/#\/schema\/person\/976030a4a8c104a0b509402bcb2a0631"},"headline":"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control","datePublished":"2026-01-06T05:20:01+00:00","dateModified":"2026-01-06T05:20:03+00:00","mainEntityOfPage":{"@id":"https:\/\/guru.today\/?p=7527"},"wordCount":448,"commentCount":0,"publisher":{"@id":"https:\/\/guru.today\/#organization"},"image":{"@id":"https:\/\/guru.today\/?p=7527#primaryimage"},"thumbnailUrl":"https:\/\/guru.today\/wp-content\/uploads\/DongA.png","articleSection":["All Stories","Everyday Economy","Top section"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/guru.today\/?p=7527#respond"]}]},{"@type":"WebPage","@id":"https:\/\/guru.today\/?p=7527","url":"https:\/\/guru.today\/?p=7527","name":"New Obesity Drug Targets Liver, Glucose Beyond GLP-1","isPartOf":{"@id":"https:\/\/guru.today\/#website"},"primaryImageOfPage":{"@id":"https:\/\/guru.today\/?p=7527#primaryimage"},"image":{"@id":"https:\/\/guru.today\/?p=7527#primaryimage"},"thumbnailUrl":"https:\/\/guru.today\/wp-content\/uploads\/DongA.png","datePublished":"2026-01-06T05:20:01+00:00","dateModified":"2026-01-06T05:20:03+00:00","description":"Early data show MetaVia\u2019s DA-1726 obesity drug may improve liver stiffness and glucose control, signaling a path beyond GLP-1\u2013only treatments.","breadcrumb":{"@id":"https:\/\/guru.today\/?p=7527#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/guru.today\/?p=7527"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/guru.today\/?p=7527#primaryimage","url":"https:\/\/guru.today\/wp-content\/uploads\/DongA.png","contentUrl":"https:\/\/guru.today\/wp-content\/uploads\/DongA.png","width":1900,"height":976},{"@type":"BreadcrumbList","@id":"https:\/\/guru.today\/?p=7527#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/guru.today\/"},{"@type":"ListItem","position":2,"name":"A New Obesity Drug Seeks to Move Beyond GLP-1, With Early Signals on Liver and Glucose Control"}]},{"@type":"WebSite","@id":"https:\/\/guru.today\/#website","url":"https:\/\/guru.today\/","name":"GURU TODAY","description":"","publisher":{"@id":"https:\/\/guru.today\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/guru.today\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/guru.today\/#organization","name":"GURU TODAY","url":"https:\/\/guru.today\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/guru.today\/#\/schema\/logo\/image\/","url":"http:\/\/54.162.83.219\/wp-content\/uploads\/Logo_white-1.png","contentUrl":"http:\/\/54.162.83.219\/wp-content\/uploads\/Logo_white-1.png","width":1000,"height":167,"caption":"GURU TODAY"},"image":{"@id":"https:\/\/guru.today\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/guru.today\/#\/schema\/person\/976030a4a8c104a0b509402bcb2a0631","name":"Jin Lee","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","caption":"Jin Lee"}}]}},"rttpg_featured_image_url":{"full":["https:\/\/guru.today\/wp-content\/uploads\/DongA.png",1900,976,false],"landscape":["https:\/\/guru.today\/wp-content\/uploads\/DongA.png",1900,976,false],"portraits":["https:\/\/guru.today\/wp-content\/uploads\/DongA.png",1900,976,false],"thumbnail":["https:\/\/guru.today\/wp-content\/uploads\/DongA-150x150.png",150,150,true],"medium":["https:\/\/guru.today\/wp-content\/uploads\/DongA-300x154.png",300,154,true],"large":["https:\/\/guru.today\/wp-content\/uploads\/DongA-1024x526.png",640,329,true],"1536x1536":["https:\/\/guru.today\/wp-content\/uploads\/DongA-1536x789.png",1536,789,true],"2048x2048":["https:\/\/guru.today\/wp-content\/uploads\/DongA.png",1900,976,false],"morenews-large":["https:\/\/guru.today\/wp-content\/uploads\/DongA-825x575.png",825,575,true],"morenews-medium":["https:\/\/guru.today\/wp-content\/uploads\/DongA-590x410.png",590,410,true]},"rttpg_author":{"display_name":"Jin Lee","author_link":"https:\/\/guru.today\/?author=7"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/guru.today\/?cat=38\" rel=\"category\">All Stories<\/a> <a href=\"https:\/\/guru.today\/?cat=32\" rel=\"category\">Everyday Economy<\/a> <a href=\"https:\/\/guru.today\/?cat=54\" rel=\"category\">Top section<\/a>","rttpg_excerpt":"MetaVia, a U.S.-based clinical-stage biotechnology company affiliated with Dong-A ST, a South Korean pharmaceutical company, has released early","_links":{"self":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/7527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7527"}],"version-history":[{"count":1,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/7527\/revisions"}],"predecessor-version":[{"id":7532,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/7527\/revisions\/7532"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/media\/7531"}],"wp:attachment":[{"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}